EUCTR2013-001141-14-AT进行中（未招募）不适用
A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDEPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIVE CHRONIC HEPATITIS B, WHO RECEIVED THERAPY FOR HEPATITIS B WITH PEGINTERFERON ALFA-2A 40KD (PEG-IFN) ± NUCLEOS(T)IDE ANALOGUE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Previously enrolled in a Roche study and treated for CHB for at least 24 weeks with Peg-IFN ± nucleoside analogue (lamivudine or entacavir) or Peg-IFN ± nucleotide analogue (adefovir) with =24-week post-treatment follow-up or;
- •Treated in general practice for CHB with Peg-IFN according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling who have no contra-indication to Peg-IFN therapy as per the local label and have been
- •treated with Peg-IFN for at least 24 weeks and have =24-week post-treatment response available at the time of blood collection.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •Patients infected with HAV, HCV, or HIV
研究者
相似试验
进行中（未招募）
不适用
A phase 4 blood sample collection study to evaluate if specific differences in genes are associated with differences in treatment response in patients with chronic liver disease caused by the hepatitis B virus who have been treated with Pegasys with or without antiviral drugs called nucleoside or nucleotide analogs.Chronic liver disease caused by the hepatitis B virus.MedDRA version: 16.1Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848EUCTR2013-001141-14-BGF.Hoffmann-La Roche Ltd.700
进行中（未招募）
不适用
A phase 4 blood sample collection study to evaluate if specific differences in genes are associated with differences in treatment response in patients with chronic liver disease caused by the hepatitis B virus who have been treated with Pegasys with or without antiviral drugs called nucleoside or nucleotide analogs.Chronic liver disease caused by the hepatitis B virus.MedDRA version: 17.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848EUCTR2013-001141-14-GRF.Hoffmann-La Roche Ltd.700
进行中（未招募）
1 期
A phase 4 blood sample collection study to evaluate if specific differences in genes are associated with differences in treatment response in patients with chronic liver disease caused by the hepatitis B virus who have been treated with Pegasys with or without antiviral drugs called nucleoside or nucleotide analogs.EUCTR2013-001141-14-FRF.Hoffmann-La Roche Ltd.700
进行中（未招募）
1 期
A phase 4 blood sample collection study to evaluate if specific differences in genes are associated with differences in treatment response in patients with chronic liver disease caused by the hepatitis B virus who have been treated with Pegasys with or without antiviral drugs called nucleoside or nucleotide analogs.EUCTR2013-001141-14-DEF.Hoffmann-La Roche Ltd.700
进行中（未招募）
不适用
A phase 4 blood sample collection study to evaluate if specific differences in genes are associated with differences in treatment response in patients with chronic liver disease caused by the hepatitis B virus who have been treated with Pegasys with or without antiviral drugs called nucleoside or nucleotide analogs.Chronic liver disease caused by the hepatitis B virus.MedDRA version: 16.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848EUCTR2013-001141-14-ITF.Hoffmann-La Roche Ltd.700